Effects of nitric oxide and antioxidants on advanced glycation end products-induced hypertrophic growth in human renal tubular cells

Toxicological Sciences

Volumn 111, Issue 1, 2009, Pages 109-119

  Huang, Jau Shyang ^a   Chuang, Lea Yea ^b   Guh, Jinn Yuh ^b   Huang, Yann Jia ^a  

^a CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Advanced glycation end products; Antioxidant; Hypertrophy; Nitric oxide; Renal proximal tubular cells

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; CYCLIC GMP DEPENDENT PROTEIN KINASE; FIBRONECTIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE P38; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; STRESS ACTIVATED PROTEIN KINASE; TAURINE;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; KIDNEY HYPERTROPHY; KIDNEY TUBULE CELL; SIGNAL TRANSDUCTION;

ANTIOXIDANTS; BLOTTING, WESTERN; CELL LINE; CELL SIZE; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; FIBRONECTINS; FLOW CYTOMETRY; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERTROPHY; KIDNEY TUBULES; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE II; ONCOGENE PROTEIN P21(RAS); RECEPTORS, IMMUNOLOGIC; S-NITROSO-N-ACETYLPENICILLAMINE;

BOVINAE;

EID: 69049109905     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfp134     Document Type: Article

References (46)

1. Ann, M. S., Shi, D. Y., Jean-Luc, W., and David, S. (1999). Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84, 489-497.
2. Bandello, F., Pognuz, R., Polito, A., Pirracchio, A., Menchini, F., and Ambesi, M. (2003). Diabetic macular edema: Classification, medical and laser therapy. Semin. Ophthalmol. 18, 251-258.
3. Berendji-Grün, D., Kolb-Bachofen, V., and Kröncke, K. D. (2001). Nitric oxide inhibits endothelial IL-1[beta]-induced ICAM-1 gene expression at the transcriptional level decreasing Sp1 and AP-1 activity. Mol. Med. 7, 748-754.
4. Bohlender, J. M., Franke, S., Stein, G., and Wolf, G. (2005). Advanced glycation end products and the kidney. Am. J. Physiol. Renal. Physiol. 289, 645-659.
5. 4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells. Cardiovasc. Res. 65, 823-831.
6. Cameron, N. E., Gibson, T. M., Nangle, M. R., and Cotter, M. A. (2005). Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann. N.Y. Acad. Sci. 1043 784-792.
7. Cerra, M. C., and Pellegrino, D. (2007). Cardiovascular cGMP-generating systems in physiological and pathological conditions. Curr. Med. Chem. 14, 585-599.
8. Chisaki, K., Nakajima, T., Iwasawa, K., Iida, H., Matsumoto, A., Tada, M., Komatsu, Y., Hirose, K., Miyamoto, K., Okuda, Y., et al. (2001). Enhancement of endothelial nitric oxide production by chenodeoxycholic acids in patients with hepatobiliary diseases. Jpn. Heart J. 42 339-353.
9. Conesa, E. L. (2001). N-acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281, 730-737.
10. Da Ros, R., Assaloni, R., and Ceriello, A. (2004). Antioxidant therapy in diabetic complications: What is new? Curr. Vasc. Pharmacol. 2, 335-341.
11. De Caterina, R., Libby, P., Peng, H. B., Thannickal, V. J., Rajavashisth, T. B., Gimbrone, M., Jr, Shin, W. S., and Liao, J. K. (1995). Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96 60-68.
12. Dimari, J. (1997). N-acetyl cysteine ameliorates ischemic renal failure. Am. J. Physiol. 272, 292-298.
13. Forbes, J. M., Fukami, K., and Cooper, M. E. (2007). Diabetic nephropathy: Where hemodynamics meets metabolism. Exp. Clin. Endocrinol. Diabetes 115, 69-84.
14. Freire-de-Lima, C. G., Xiao, Y. Q., Gardai, S. J., Bratton, D. L., Schiemann, W. P., and Henson, P. M. (2006). Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J. Biol. Chem. 281, 38376-38384.
15. Fukami, K., Ueda, S., Yamagishi, S., Kato, S., Inagaki, Y., Takeuchi, M., Motomiya, Y., Bucala, R., Iida, S., Tamaki, K., et al. (2004). AGE activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int. 66, 2137-2147.
16. Fukami, K., Yamagishi, S., Ueda, S., and Okuda, S. (2007). Novel therapeutic targets for diabetic nephropathy. Endocr. Metab. Immun. Disord. Drug Targets 7, 83-92.
17. Giunti, S., Barit, D., and Cooper, M. E. (2006). Mechanisms of diabetic nephropathy: Role of hypertension. Hypertension 48, 519-526.
18. Ha, H., and Lee, H. B. (2005). Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney. Nephrology (Carlton) 10, 7-10.
19. Haber, C. A., Lam, T. K., Yu, Z., Gupta, N., Goh, T., Bogdanovic, E., Giacca, A., and Fantus, I. G. (2003). N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: Possible role of oxidative stress. Am. J. Physiol. Endocrinol. Metab. 285, E744-E753.
20. Huang, J. S., Chuang, L. Y., Guh, J. Y., Chen, C. J., Yang, Y. L., Chiang, T. A., Hung, M. Y., and Liao, T. N. (2005). Effect of nitric oxide-cGMP- dependent protein kinase activation on advanced glycation endproduct- induced proliferation in renal fibroblasts. J. Am. Soc. Nephrol. 16, 2318-2329.
21. Jiang, B., Haverty, M., and Brecher, P. (1999). N-acetyl-L-cysteine enhances interleukin-1 beta-induced nitric oxide synthase expression. Hypertension 34, 574-579.
22. Levine, D. Z. (2006). Hyperfiltration, nitric oxide, and diabetic nephropathy. Curr. Hypertens. Rep. 8, 153-157.
23. Miyazaki-Akita, A., Hayashi, T., Ding, Q. F., Shiraishi, H., Nomura, T., Hattori, Y., and Iguchi, A. (2007). 17beta-estradiol antagonizes the down-regulation of endothelial nitric-oxide synthase and GTP cyclohydrolase I by high glucose: Relevance to postmenopausal diabetic cardiovascular disease. J. Pharmacol. Exp. Ther. 320, 591-598.
24. Mustonen, H., Kiviluoto, T., Puolakkainen, P., Paimela, H., Mentula, P., Kemppainen, E., and Kivilaakso, E. (2008). Taurocholate-induced nitric oxide signaling and the ensuing production of reactive oxygen species lead to an increase in epithelial permeability in cultivated mouse gastric epithelium. Dig. Dis. Sci. 53, 3119-3127.
25. Nakagawa, T. (2007). Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: An explanation for the paradoxical effects of VEGF in renal disease. Am. J. Physiol. Renal. Physiol. 292 1665-1672.
26. Nakaya, Y., Minami, A., Harada, N., Sakamoto, S., Niwa, Y., and Ohnaka, M. (2000). Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous type 2 diabetes. Am. J. Clin. Nutr. 71, 54-58.
27. Niedowicz, D. M., and Daleke, D. L. (2005). The role of oxidative stress in diabetic complications. Cell. Biochem. Biophys. 43, 289-330.
28. Nobushige, T., Hideto, Y., Sho-ichi, Y., Hideki, F., Yasuhiko, Y., and Hiroshi, Y. (1995). The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-α through nuclear factor-κB, and by 17β-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem. 275, 25781-25790.
29. Noh, H., Ha, H., Yu, M. R., Kang, S. W., Choi, K. H., Han, D. S., and Lee, H. Y. (2002). High glucose increases inducible NO production in cultured rat mesangial cells. Possible role in fibronectin production. Nephron 90, 78-85.
30. Peng, H. B., Rajavashisth, T. B., Libby, P., and Liao, J. K. (1995). Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells. J. Biol. Chem. 270 17050-17055.
31. Prabhakar, S. S. (2001). Tetrahydrobiopterin reverses the inhibition of nitric oxide by high glucose in cultured murine mesangial cells. Am. J. Physiol. Renal. Physiol. 281, 179-188.
32. Salom, M. G. (1998). Protective effect of N-acetyl-L-cysteine on the renal failure induced by inferior vena cava occlusion. Transplantation 65, 1315-1321.
33. Sato, T., Iwaki, M., Shimogaito, N., Wu, X., Yamagishi, S., and Takeuchi, M. (2006). TAGE (toxic AGE) theory in diabetic complications. Curr. Mol. Med. 6, 351-358.
34. Schrijvers, B. F., De Vriese, A. S., and Flyvbjerg, A. (2004). From hyperglycemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr. Rev. 25, 971-1010.
35. Schutta, M. H. (2007). Diabetes and hypertension: Epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J. Cardiometab. Syndr. 2, 124-130.
36. Sho-ichi, Y., Hisashi, A., Kazuo, N., Takanori, M., Yuko, J., Katsuhiko, T., Masayoshi, T., Mika, E., Kumiko, F., Asuka, H., Yoshiyuki, S., and Tsutomu, I. (2006). Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metab. Clin. Exp. 55, 1227-1231.
37. Studer, R. K., DeRubertis, F. R., and Craven, P. A. (1996). Nitric oxide suppresses increases in mesangial cell protein kinase C, transforming growth factor beta, and fibronectin synthesis induced by thromboxane. J. Am. Soc. Nephrol. 7, 999-1005.
38. Tan, A. L., Forbes, J. M., and Cooper, M. E. (2007). AGE, RAGE, and ROS in diabetic nephropathy. Semin. Nephrol. 27, 130-143.
39. Thorsten, O., Estelle, L., Arnaud, G., Michael, K., Nina, D., Bernd, W., Claus, W. H., Peter, M. K., and Günter, F. (2007). Structural and functional insights into RAGE activation by multimeric S100B. EMBO J. 26, 3868-3878.
40. Verzola, D., Bertolotto, M. B., Villaggio, B., Ottonello, L., Dallegri, F., Frumento, G., Berruti, V., Gandolfo, M. T., Garibotto, G., and Deferran, G. (2002). Taurine prevents apoptosis induced by high ambient glucose in human tubule renal cells. J. Investig. Med. 50, 443-451.
41. Wilcox, C. S. (2005). Oxidative stress and nitric oxide deficiency in the kidney: A critical link to hypertension? Am. J. Physiol. Regul. Integr. Comp. Physiol. 289, 913-935.
42. Wolf, G. (2000). Cell cycle regulation in diabetic nephropathy. Kidney Int. 77, 59-66.
43. Xia, Z., Nagareddy, P. R., Guo, Z., Zhang, W., and McNeill, J. H. (2006). Antioxidant N-acetylcysteine restores systemic nitric oxide availability and corrects depressions in arterial blood pressure and heart rate in diabetic rats. Free Radic. Res. 40, 175-84.
44. Xu, B., Ji, Y., Yao, K., Cao, Y. X., and Ferro, A. (2005). Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: Relevance to diabetes. Clin. Sci. (Lond.) 109, 439-446.
45. Yamamoto, Y., Yonekura, H., Watanabe, T., Sakurai, S., Li, H., Harashima, A., Myint, K. M., Osawa, M., Takeuchi, A., Takeuchi, M., and Yamamoto, H. (2007). Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res. Clin. Pract. 77, 30-40.
46. Zhou, Z. H., Jiang, J. L., Peng, J., Deng, H. W., and Li, Y. J. (2002). Reversal of tolerance to nitroglycerin with N-acetylcysteine or captopril: A role of calcitonin gene related peptide. Eur. J. Pharmacol. 439, 129-134.